Lilly, Medtronic Enter Parkinson's Collaboration
April 26, 2011 | Eli Lilly and Company and Medtronic have entered into a collaboration to research and develop a new approach to treating Parkinson’s disease that involves delivering a potential new medicine to the brain using an implantable drug delivery system. The goal of the collaboration is to develop a therapeutic approach for Parkinson’s disease that combines the strengths of Lilly’s biologic, a modified form of glial cell derived neurotrophic factor (GDNF), with Medtronic’s implantable drug infusion system technology. Medtronic
